{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:53:13Z","timestamp":1791827593266,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0532204"],"award-info":[{"award-number":["2024ZD0532204"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0532204"],"award-info":[{"award-number":["2024ZD0532204"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0532204"],"award-info":[{"award-number":["2024ZD0532204"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0532204"],"award-info":[{"award-number":["2024ZD0532204"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0532204"],"award-info":[{"award-number":["2024ZD0532204"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0532204"],"award-info":[{"award-number":["2024ZD0532204"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"DOI":"10.1007\/s00198-026-08239-4","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:39:04Z","timestamp":1791826744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk: real-world evidence from a retrospective cohort study"],"prefix":"10.1007","author":[{"given":"Shuquan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruotong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhi","family":"Jiajue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijia","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7337-9982","authenticated-orcid":false,"given":"Yue","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-5536","authenticated-orcid":false,"given":"Weibo","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"21","key":"8239_CR1","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1056\/NEJMcp2307353","volume":"389","author":"MD Walker","year":"2023","unstructured":"Walker MD, Shane E (2023) Postmenopausal osteoporosis. N Engl J Med 389(21):1979\u20131991. https:\/\/doi.org\/10.1056\/NEJMcp2307353","journal-title":"N Engl J Med"},{"issue":"3","key":"8239_CR2","doi-asserted-by":"publisher","first-page":"Itc17","DOI":"10.7326\/aitc201708010","volume":"167","author":"KE Ensrud","year":"2017","unstructured":"Ensrud KE, Crandall CJ (2017) Osteoporosis. Ann Intern Med 167(3):Itc17\u2013itc32. https:\/\/doi.org\/10.7326\/aitc201708010","journal-title":"Ann Intern Med"},{"issue":"20","key":"8239_CR3","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1001\/jama.2019.15781","volume":"322","author":"KE Ensrud","year":"2019","unstructured":"Ensrud KE, Crandall CJ (2019) Bisphosphonates for postmenopausal osteoporosis. JAMA 322(20):2017\u20132018. https:\/\/doi.org\/10.1001\/jama.2019.15781","journal-title":"JAMA"},{"issue":"1","key":"8239_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.11005\/jbm.2017.24.1.37","volume":"24","author":"JH Byun","year":"2017","unstructured":"Byun JH, Jang S, Lee S et al (2017) The efficacy of bisphosphonates for prevention of osteoporotic fracture: an update meta-analysis. J Bone Metab 24(1):37\u201349. https:\/\/doi.org\/10.11005\/jbm.2017.24.1.37","journal-title":"J Bone Metab"},{"issue":"18","key":"8239_CR5","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799\u20131809. https:\/\/doi.org\/10.1056\/NEJMoa074941","journal-title":"N Engl J Med"},{"key":"8239_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.bone.2016.05.013","volume":"89","author":"J Sanderson","year":"2016","unstructured":"Sanderson J, Martyn-St James M, Stevens J et al (2016) Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis. Bone 89:52\u201358. https:\/\/doi.org\/10.1016\/j.bone.2016.05.013","journal-title":"Bone"},{"issue":"9","key":"8239_CR7","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jcms.2017.05.028","volume":"45","author":"S Aljohani","year":"2017","unstructured":"Aljohani S, Fliefel R, Ihbe J, K\u00fchnisch J, Ehrenfeld M, Otto S (2017) What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review. J Craniomaxill Surg 45(9):1493\u20131502. https:\/\/doi.org\/10.1016\/j.jcms.2017.05.028","journal-title":"J Craniomaxill Surg"},{"issue":"8","key":"8239_CR8","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJMoa1916525","volume":"383","author":"DM Black","year":"2020","unstructured":"Black DM, Geiger EJ, Eastell R et al (2020) Atypical Femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med 383(8):743\u2013753. https:\/\/doi.org\/10.1056\/NEJMoa1916525","journal-title":"N Engl J Med"},{"issue":"1","key":"8239_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Min Res 30(1):3\u201323. https:\/\/doi.org\/10.1002\/jbmr.2405","journal-title":"J Bone Min Res"},{"issue":"10","key":"8239_CR10","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S Khosla","year":"2007","unstructured":"Khosla S, Burr D, Cauley J et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Min Res 22(10):1479\u20131491. https:\/\/doi.org\/10.1359\/jbmr.0707onj","journal-title":"J Bone Min Res"},{"issue":"2","key":"8239_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","volume":"68","author":"JC Lo","year":"2010","unstructured":"Lo JC, O\u2019Ryan FS, Gordon NP et al (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 68(2):243\u2013253. https:\/\/doi.org\/10.1016\/j.joms.2009.03.050","journal-title":"J Oral Maxillofac Surg"},{"issue":"8","key":"8239_CR12","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1001\/jama.2011.190","volume":"305","author":"LY Park-Wyllie","year":"2011","unstructured":"Park-Wyllie LY, Mamdani MM, Juurlink DN et al (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. Jama 305(8):783\u2013789. https:\/\/doi.org\/10.1001\/jama.2011.190","journal-title":"Jama"},{"issue":"18","key":"8239_CR13","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","volume":"364","author":"J Schilcher","year":"2011","unstructured":"Schilcher J, Micha\u00eblsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364(18):1728\u20131737. https:\/\/doi.org\/10.1056\/NEJMoa1010650","journal-title":"N Engl J Med"},{"issue":"1","key":"8239_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Min Res 29(1):1\u201323. https:\/\/doi.org\/10.1002\/jbmr.1998","journal-title":"J Bone Min Res"},{"issue":"3","key":"8239_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/s8756-3282(03)00112-1","volume":"33","author":"YZ Bagger","year":"2003","unstructured":"Bagger YZ, Tank\u00f3 LB, Alexandersen P, Ravn P, Christiansen C (2003) Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 33(3):301\u2013307. https:\/\/doi.org\/10.1016\/s8756-3282(03)00112-1","journal-title":"Bone"},{"issue":"12","key":"8239_CR16","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350(12):1189\u20131199. https:\/\/doi.org\/10.1056\/NEJMoa030897","journal-title":"N Engl J Med"},{"issue":"4","key":"8239_CR17","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1210\/jcem.85.4.6549","volume":"85","author":"P Ravn","year":"2000","unstructured":"Ravn P, Weiss SR, Rodriguez-Portales JA et al (2000) Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab 85(4):1492\u20131497. https:\/\/doi.org\/10.1210\/jcem.85.4.6549","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"8239_CR18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"RG Russell","year":"2008","unstructured":"Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19(6):733\u2013759. https:\/\/doi.org\/10.1007\/s00198-007-0540-8","journal-title":"Osteoporos Int"},{"issue":"24","key":"8239_CR19","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. Jama 296(24):2927\u20132938. https:\/\/doi.org\/10.1001\/jama.296.24.2927","journal-title":"Jama"},{"issue":"2","key":"8239_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S et al (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Min Res 27(2):243\u2013254. https:\/\/doi.org\/10.1002\/jbmr.1494","journal-title":"J Bone Min Res"},{"issue":"1","key":"8239_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jbmr.2708","volume":"31","author":"RA Adler","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC et al (2016) Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Min Res 31(1):16\u201335. https:\/\/doi.org\/10.1002\/jbmr.2708","journal-title":"J Bone Min Res"},{"issue":"7","key":"8239_CR22","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1002\/jbmr.3420","volume":"33","author":"AL Adams","year":"2018","unstructured":"Adams AL, Adams JL, Raebel MA et al (2018) Bisphosphonate drug holiday and fracture risk: a population-based cohort study. J Bone Min Res 33(7):1252\u20131259. https:\/\/doi.org\/10.1002\/jbmr.3420","journal-title":"J Bone Min Res"},{"issue":"11","key":"8239_CR23","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s00198-008-0604-4","volume":"19","author":"JR Curtis","year":"2008","unstructured":"Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG (2008) Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 19(11):1613\u20131620. https:\/\/doi.org\/10.1007\/s00198-008-0604-4","journal-title":"Osteoporos Int"},{"issue":"5","key":"8239_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/mlr.0000000000001294","volume":"58","author":"JR Curtis","year":"2020","unstructured":"Curtis JR, Saag KG, Arora T et al (2020) Duration of bisphosphonate drug holidays and associated fracture risk. Med Care 58(5):419\u2013426. https:\/\/doi.org\/10.1097\/mlr.0000000000001294","journal-title":"Med Care"},{"issue":"12","key":"8239_CR25","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1007\/s00198-017-4215-9","volume":"28","author":"MA Mignot","year":"2017","unstructured":"Mignot MA, Taisne N, Legroux I, Cortet B, Paccou J (2017) Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk. Osteoporos Int 28(12):3431\u20133438. https:\/\/doi.org\/10.1007\/s00198-017-4215-9","journal-title":"Osteoporos Int"},{"key":"8239_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115431","volume":"138","author":"J Pfeilschifter","year":"2020","unstructured":"Pfeilschifter J, Steinebach I, Trampisch HJ, Rudolf H (2020) Bisphosphonate drug holidays: Risk of fractures and mortality in a prospective cohort study. Bone 138:115431. https:\/\/doi.org\/10.1016\/j.bone.2020.115431","journal-title":"Bone"},{"issue":"6","key":"8239_CR27","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00198-020-05745-x","volume":"32","author":"AS S\u00f8lling","year":"2021","unstructured":"S\u00f8lling AS, Christensen DH, Darvalics B, Harsl\u00f8f T, Thomsen RW, Langdahl B (2021) Fracture rates in patients discontinuing alendronate treatment in real life: a population-based cohort study. Osteoporos Int 32(6):1103\u20131115. https:\/\/doi.org\/10.1007\/s00198-020-05745-x","journal-title":"Osteoporos Int"},{"issue":"4","key":"8239_CR28","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00198-018-4791-3","volume":"30","author":"S Nayak","year":"2019","unstructured":"Nayak S, Greenspan SL (2019) A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk. Osteoporos Int 30(4):705\u2013720. https:\/\/doi.org\/10.1007\/s00198-018-4791-3","journal-title":"Osteoporos Int"},{"key":"8239_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.maturitas.2017.04.008","volume":"101","author":"P Anagnostis","year":"2017","unstructured":"Anagnostis P, Paschou SA, Mintziori G et al (2017) Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas 101:23\u201330. https:\/\/doi.org\/10.1016\/j.maturitas.2017.04.008","journal-title":"Maturitas"},{"issue":"9041","key":"8239_CR30","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/s0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fract Interven Trial Res Group Lancet 348(9041):1535\u20131541. https:\/\/doi.org\/10.1016\/s0140-6736(96)07088-2","journal-title":"Fract Interven Trial Res Group Lancet"},{"issue":"8","key":"8239_CR31","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/jbmr.1644","volume":"27","author":"RM Jacques","year":"2012","unstructured":"Jacques RM, Boonen S, Cosman F et al (2012) Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Min Res 27(8):1627\u20131634. https:\/\/doi.org\/10.1002\/jbmr.1644","journal-title":"J Bone Min Res"},{"issue":"6","key":"8239_CR32","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s001980170087","volume":"12","author":"Y Lu","year":"2001","unstructured":"Lu Y, Fuerst T, Hui S, Genant HK (2001) Standardization of bone mineral density at femoral neck, trochanter and Ward\u2019s triangle. Osteoporos Int 12(6):438\u2013444. https:\/\/doi.org\/10.1007\/s001980170087","journal-title":"Osteoporos Int"},{"issue":"9","key":"8239_CR33","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1359\/jbmr.1997.12.9.1463","volume":"12","author":"SL Hui","year":"1997","unstructured":"Hui SL, Gao S, Zhou XH et al (1997) Universal standardization of bone density measurements: a method with optimal properties for calibration among several instruments. J Bone Min Res 12(9):1463\u20131470. https:\/\/doi.org\/10.1359\/jbmr.1997.12.9.1463","journal-title":"J Bone Min Res"},{"issue":"14","key":"8239_CR34","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.12114\/j.issn.1007-9572.2023.0121","volume":"26","author":"CSoOaBM Research","year":"2023","unstructured":"Research CSoOaBM (2023) Guidelines for the diagnosis and treatment of primary osteoporosis (2022). Chin Gen Pract 26(14):1671\u20131691. https:\/\/doi.org\/10.12114\/j.issn.1007-9572.2023.0121","journal-title":"Chin Gen Pract"},{"issue":"11","key":"8239_CR35","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1007\/s00198-013-2413-7","volume":"24","author":"JA Kanis","year":"2013","unstructured":"Kanis JA, Adachi JD, Cooper C et al (2013) Standardising the descriptive epidemiology of osteoporosis: recommendations from the Epidemiology and Quality of Life Working Group of IOF. Osteoporos Int 24(11):2763\u20132764. https:\/\/doi.org\/10.1007\/s00198-013-2413-7","journal-title":"Osteoporos Int"},{"issue":"5","key":"8239_CR36","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s001980050093","volume":"8","author":"AC Looker","year":"1998","unstructured":"Looker AC, Wahner HW, Dunn WL et al (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8(5):468\u2013489. https:\/\/doi.org\/10.1007\/s001980050093","journal-title":"Osteoporos Int"},{"issue":"1","key":"8239_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bone.2011.01.014","volume":"49","author":"S Cremers","year":"2011","unstructured":"Cremers S, Papapoulos S (2011) Pharmacology of bisphosphonates. Bone 49(1):42\u201349. https:\/\/doi.org\/10.1016\/j.bone.2011.01.014","journal-title":"Bone"},{"issue":"5","key":"8239_CR38","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","volume":"38","author":"GH Nancollas","year":"2006","unstructured":"Nancollas GH, Tang R, Phipps RJ et al (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38(5):617\u2013627. https:\/\/doi.org\/10.1016\/j.bone.2005.05.003","journal-title":"Bone"},{"issue":"3","key":"8239_CR39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2407031","volume":"392","author":"MJ Bolland","year":"2025","unstructured":"Bolland MJ, Nisa Z, Mellar A et al (2025) Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age. N Engl J Med 392(3):239\u2013248. https:\/\/doi.org\/10.1056\/NEJMoa2407031","journal-title":"N Engl J Med"},{"issue":"12","key":"8239_CR40","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1210\/jc.2014-1971","volume":"99","author":"F Cosman","year":"2014","unstructured":"Cosman F, Cauley JA, Eastell R et al (2014) Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? J Clin Endocrinol Metab 99(12):4546\u20134554. https:\/\/doi.org\/10.1210\/jc.2014-1971","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"8239_CR41","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/jbmr.3654","volume":"34","author":"TY Kim","year":"2019","unstructured":"Kim TY, Bauer DC, McNabb BL et al (2019) Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I Trials. J Bone Min Res 34(5):810\u2013816. https:\/\/doi.org\/10.1002\/jbmr.3654","journal-title":"J Bone Min Res"},{"key":"8239_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.106091","volume":"96","author":"Y Fang","year":"2020","unstructured":"Fang Y, He W, Wang H, Wu M (2020) Key considerations in the design of real-world studies. Contemp Clin Trials 96:106091. https:\/\/doi.org\/10.1016\/j.cct.2020.106091","journal-title":"Contemp Clin Trials"},{"issue":"7","key":"8239_CR43","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1001\/jamainternmed.2014.1232","volume":"174","author":"DC Bauer","year":"2014","unstructured":"Bauer DC, Schwartz A, Palermo L et al (2014) Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med 174(7):1126\u20131134. https:\/\/doi.org\/10.1001\/jamainternmed.2014.1232","journal-title":"JAMA Intern Med"},{"issue":"6","key":"8239_CR44","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/jbmr.1864","volume":"28","author":"BL McNabb","year":"2013","unstructured":"McNabb BL, Vittinghoff E, Schwartz AV et al (2013) BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. J Bone Min Res 28(6):1319\u20131327. https:\/\/doi.org\/10.1002\/jbmr.1864","journal-title":"J Bone Min Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08239-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08239-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08239-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:39:06Z","timestamp":1791826746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-08239-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":44,"alternative-id":["8239"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08239-4","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shuquan Zhang, Zhixiang Wang, Ruotong Zhou, Wei Yu, Qianqian Pang, Ruizhi Jiajue, Lijia Cui, Wei Liu, Yan Jiang, Mei Li, Xiaoping Xing, Ou Wang, Yue Chi, and Weibo Xia declare that they have no conflict of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}